The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Voyager Therapeutics (NASDAQ:VYGR) reported second-quarter results. Shares rose 7.9% to $3.27. Revenues were 31% below analyst predictions, while losses of $0.40 per share were 20% smaller than expected. Analysts now forecast 2026 revenue of $46.0m (up from $39.3m) and losses of $1.87 per share, with the consensus price target unchanged at $14.89.
How this was made
The 30-second read
Why it matters
Analysts lifted 2026 revenue expectations to $46.0m (from $39.3m) but also increased expected losses to $1.87/share (from $1.61/share). The consensus price target remains $14.89, implying mixed sentiment and valuation stability despite forecast changes.
Market read
Traders get a mixed signal: revenue growth expectations improve, but loss forecasts worsen, with valuation expectations largely unchanged.
What to watch
The article highlights forecast dispersion (price targets from $8 to $25) but does not explain the underlying drivers, which could mean risk is concentrated in a few assumptions not captured by the headline consensus.
Background
The article summarizes Voyager Therapeutics’ latest quarterly results and the resulting consensus forecast updates from six analysts.
Ticker impact
Voyager Therapeutics shares rose 7.9% after reporting results, while analysts updated 2026 revenue to $46.0m and losses to $1.87/share.
Near-term upside may be capped by rising loss forecasts, with follow-through dependent on whether revenue growth translates into improving profitability.
The article provides specific updated consensus figures (revenue up vs prior, losses up vs prior) and notes no meaningful change to the $14.89 consensus price target, implying mixed fundamentals rather than a clear re-rating.
Market effects
Limited, as the piece is company-specific and does not disclose new sector-wide regulatory or clinical developments.
None indicated beyond the single-name move.
None indicated.
Counterpoint
The unchanged consensus price target despite higher revenue and higher losses suggests the market may already be pricing the same fundamental trajectory, so the stock move could fade without new clinical or operational catalysts.
Key entities
- companyVoyager Therapeutics, Inc.
NASDAQ-listed biotech whose quarterly results and updated analyst forecasts are summarized.
- analyst_groupVoyager Therapeutics analysts (6)
Provide updated 2026 revenue and loss-per-share forecasts and maintain a largely unchanged consensus price target.
